Switching to duloxetine from selective serotonin reuptake inhibitors in non- or partial responders: Results from a Spanish sample
Objectives. To evaluate the efficacy and safety of switching from a selective serotonin reuptake inhibitor (SSRI) to duloxetine in non- or partial responders. Methods. This is a post-hoc analysis of the pooled data of the Spanish sample from an open-label, multicentre study. Additionally, a 6-month...
Gespeichert in:
| Veröffentlicht in: | International journal of psychiatry in clinical practice 2009-01, Vol.13 (2), p.100-108 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 108 |
|---|---|
| container_issue | 2 |
| container_start_page | 100 |
| container_title | International journal of psychiatry in clinical practice |
| container_volume | 13 |
| creator | Irene, Romera Luis, Montejo Angel Helena, Delgado-Cohen David, Perahia Ramon, Domenech Josep Inmaculada, Gilaberte |
| description | Objectives. To evaluate the efficacy and safety of switching from a selective serotonin reuptake inhibitor (SSRI) to duloxetine in non- or partial responders. Methods. This is a post-hoc analysis of the pooled data of the Spanish sample from an open-label, multicentre study. Additionally, a 6-month continuation safety phase was performed. Results. A total of 156 patients were switched to duloxetine from SSRIs. More than 83% completed the acute phase, of whom 75% went into the continuation phase. At baseline, the mean duration of SSRI treatment was 71.2 weeks and the HAM-D17 mean score was 22.4. In the acute-phase, symptoms severity significantly improved after 10 weeks of duloxetine treatment as measured by mean change from baseline in HAM-D17 total score (−10.5; P |
| doi_str_mv | 10.1080/13651500802578975 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_24916728</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1535625329</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-be5260aee0e429ebe6e3cf789b4485bf6cdecbc720587dabbb01be2e4dd4992c3</originalsourceid><addsrcrecordid>eNp9kM9rFzEQxYMotlb_AC-So5fVJLvJ7qqXUvwFBcHqOSTZWTc1m6yTrLVH_3Mj3yqI0NM8mM97zDxCHnP2jLOBPeetklyyKoXsh7GXd8gx73re8H4Y7lZd900F-BF5kPMlY0wqJe-TI9GNXPViOCY_L658cYuPX2hJdNpD-gHFR6AzppVmCOCK_w5VYSop-kgR9q2Yr0B9XLz1JWGuksYUG5qQbgaLN6FieUtxAswv6EfIeyj5kGnoxWaizwvNZt0CPCT3ZhMyPLqZJ-Tzm9efzt415x_evj87PW9cx1RpLEihmAFg0IkRLCho3Vy_tl03SDsrN4GzrhdMDv1krLWMWxDQTVM3jsK1J-TpIXfD9G2HXPTqs4MQTIS0Z81lK5WQrRgryg-ow5Qzwqw39KvBa82Z_t28_q_56nlyE7_bFaa_jj9VV-DVAfBxTriaq4Rh0sVch4Qzmuh81u1t-S__sS9gQlmcQdCXacdYq7vlul_OnqeT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1535625329</pqid></control><display><type>article</type><title>Switching to duloxetine from selective serotonin reuptake inhibitors in non- or partial responders: Results from a Spanish sample</title><source>Taylor & Francis:Master (3349 titles)</source><source>Taylor & Francis Medical Library - CRKN</source><creator>Irene, Romera ; Luis, Montejo Angel ; Helena, Delgado-Cohen ; David, Perahia ; Ramon, Domenech Josep ; Inmaculada, Gilaberte</creator><creatorcontrib>Irene, Romera ; Luis, Montejo Angel ; Helena, Delgado-Cohen ; David, Perahia ; Ramon, Domenech Josep ; Inmaculada, Gilaberte</creatorcontrib><description>Objectives. To evaluate the efficacy and safety of switching from a selective serotonin reuptake inhibitor (SSRI) to duloxetine in non- or partial responders. Methods. This is a post-hoc analysis of the pooled data of the Spanish sample from an open-label, multicentre study. Additionally, a 6-month continuation safety phase was performed. Results. A total of 156 patients were switched to duloxetine from SSRIs. More than 83% completed the acute phase, of whom 75% went into the continuation phase. At baseline, the mean duration of SSRI treatment was 71.2 weeks and the HAM-D17 mean score was 22.4. In the acute-phase, symptoms severity significantly improved after 10 weeks of duloxetine treatment as measured by mean change from baseline in HAM-D17 total score (−10.5; P<0.001) and all secondary efficacy measures, including painful symptoms. Response (≥50% decrease in HAM-D17 total score) and remission rates (HAM-D17 total score ≤ 7) were 52.9 and 27.7%, respectively. The most common adverse events reported in both phases were headache (11.5% [acute]; 6.1% [continuation]) and nausea (6.4% [acute]; 5.1% [continuation]). Conclusions. In a population of Spanish SSRI non- and partial responders, switch to duloxetine was associated with significant improvement in emotional and painful symptoms of depression. Duloxetine was well tolerated and safe during both phases.</description><identifier>ISSN: 1365-1501</identifier><identifier>EISSN: 1471-1788</identifier><identifier>DOI: 10.1080/13651500802578975</identifier><identifier>PMID: 24916728</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Duloxetine ; major depressive disorder ; remission ; response ; selective serotonin reuptake inhibitor</subject><ispartof>International journal of psychiatry in clinical practice, 2009-01, Vol.13 (2), p.100-108</ispartof><rights>2009 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-be5260aee0e429ebe6e3cf789b4485bf6cdecbc720587dabbb01be2e4dd4992c3</citedby><cites>FETCH-LOGICAL-c406t-be5260aee0e429ebe6e3cf789b4485bf6cdecbc720587dabbb01be2e4dd4992c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/13651500802578975$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/13651500802578975$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,59647,59753,60436,60542,61221,61256,61402,61437</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24916728$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Irene, Romera</creatorcontrib><creatorcontrib>Luis, Montejo Angel</creatorcontrib><creatorcontrib>Helena, Delgado-Cohen</creatorcontrib><creatorcontrib>David, Perahia</creatorcontrib><creatorcontrib>Ramon, Domenech Josep</creatorcontrib><creatorcontrib>Inmaculada, Gilaberte</creatorcontrib><title>Switching to duloxetine from selective serotonin reuptake inhibitors in non- or partial responders: Results from a Spanish sample</title><title>International journal of psychiatry in clinical practice</title><addtitle>Int J Psychiatry Clin Pract</addtitle><description>Objectives. To evaluate the efficacy and safety of switching from a selective serotonin reuptake inhibitor (SSRI) to duloxetine in non- or partial responders. Methods. This is a post-hoc analysis of the pooled data of the Spanish sample from an open-label, multicentre study. Additionally, a 6-month continuation safety phase was performed. Results. A total of 156 patients were switched to duloxetine from SSRIs. More than 83% completed the acute phase, of whom 75% went into the continuation phase. At baseline, the mean duration of SSRI treatment was 71.2 weeks and the HAM-D17 mean score was 22.4. In the acute-phase, symptoms severity significantly improved after 10 weeks of duloxetine treatment as measured by mean change from baseline in HAM-D17 total score (−10.5; P<0.001) and all secondary efficacy measures, including painful symptoms. Response (≥50% decrease in HAM-D17 total score) and remission rates (HAM-D17 total score ≤ 7) were 52.9 and 27.7%, respectively. The most common adverse events reported in both phases were headache (11.5% [acute]; 6.1% [continuation]) and nausea (6.4% [acute]; 5.1% [continuation]). Conclusions. In a population of Spanish SSRI non- and partial responders, switch to duloxetine was associated with significant improvement in emotional and painful symptoms of depression. Duloxetine was well tolerated and safe during both phases.</description><subject>Duloxetine</subject><subject>major depressive disorder</subject><subject>remission</subject><subject>response</subject><subject>selective serotonin reuptake inhibitor</subject><issn>1365-1501</issn><issn>1471-1788</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp9kM9rFzEQxYMotlb_AC-So5fVJLvJ7qqXUvwFBcHqOSTZWTc1m6yTrLVH_3Mj3yqI0NM8mM97zDxCHnP2jLOBPeetklyyKoXsh7GXd8gx73re8H4Y7lZd900F-BF5kPMlY0wqJe-TI9GNXPViOCY_L658cYuPX2hJdNpD-gHFR6AzppVmCOCK_w5VYSop-kgR9q2Yr0B9XLz1JWGuksYUG5qQbgaLN6FieUtxAswv6EfIeyj5kGnoxWaizwvNZt0CPCT3ZhMyPLqZJ-Tzm9efzt415x_evj87PW9cx1RpLEihmAFg0IkRLCho3Vy_tl03SDsrN4GzrhdMDv1krLWMWxDQTVM3jsK1J-TpIXfD9G2HXPTqs4MQTIS0Z81lK5WQrRgryg-ow5Qzwqw39KvBa82Z_t28_q_56nlyE7_bFaa_jj9VV-DVAfBxTriaq4Rh0sVch4Qzmuh81u1t-S__sS9gQlmcQdCXacdYq7vlul_OnqeT</recordid><startdate>20090101</startdate><enddate>20090101</enddate><creator>Irene, Romera</creator><creator>Luis, Montejo Angel</creator><creator>Helena, Delgado-Cohen</creator><creator>David, Perahia</creator><creator>Ramon, Domenech Josep</creator><creator>Inmaculada, Gilaberte</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090101</creationdate><title>Switching to duloxetine from selective serotonin reuptake inhibitors in non- or partial responders: Results from a Spanish sample</title><author>Irene, Romera ; Luis, Montejo Angel ; Helena, Delgado-Cohen ; David, Perahia ; Ramon, Domenech Josep ; Inmaculada, Gilaberte</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-be5260aee0e429ebe6e3cf789b4485bf6cdecbc720587dabbb01be2e4dd4992c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Duloxetine</topic><topic>major depressive disorder</topic><topic>remission</topic><topic>response</topic><topic>selective serotonin reuptake inhibitor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Irene, Romera</creatorcontrib><creatorcontrib>Luis, Montejo Angel</creatorcontrib><creatorcontrib>Helena, Delgado-Cohen</creatorcontrib><creatorcontrib>David, Perahia</creatorcontrib><creatorcontrib>Ramon, Domenech Josep</creatorcontrib><creatorcontrib>Inmaculada, Gilaberte</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of psychiatry in clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Irene, Romera</au><au>Luis, Montejo Angel</au><au>Helena, Delgado-Cohen</au><au>David, Perahia</au><au>Ramon, Domenech Josep</au><au>Inmaculada, Gilaberte</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Switching to duloxetine from selective serotonin reuptake inhibitors in non- or partial responders: Results from a Spanish sample</atitle><jtitle>International journal of psychiatry in clinical practice</jtitle><addtitle>Int J Psychiatry Clin Pract</addtitle><date>2009-01-01</date><risdate>2009</risdate><volume>13</volume><issue>2</issue><spage>100</spage><epage>108</epage><pages>100-108</pages><issn>1365-1501</issn><eissn>1471-1788</eissn><abstract>Objectives. To evaluate the efficacy and safety of switching from a selective serotonin reuptake inhibitor (SSRI) to duloxetine in non- or partial responders. Methods. This is a post-hoc analysis of the pooled data of the Spanish sample from an open-label, multicentre study. Additionally, a 6-month continuation safety phase was performed. Results. A total of 156 patients were switched to duloxetine from SSRIs. More than 83% completed the acute phase, of whom 75% went into the continuation phase. At baseline, the mean duration of SSRI treatment was 71.2 weeks and the HAM-D17 mean score was 22.4. In the acute-phase, symptoms severity significantly improved after 10 weeks of duloxetine treatment as measured by mean change from baseline in HAM-D17 total score (−10.5; P<0.001) and all secondary efficacy measures, including painful symptoms. Response (≥50% decrease in HAM-D17 total score) and remission rates (HAM-D17 total score ≤ 7) were 52.9 and 27.7%, respectively. The most common adverse events reported in both phases were headache (11.5% [acute]; 6.1% [continuation]) and nausea (6.4% [acute]; 5.1% [continuation]). Conclusions. In a population of Spanish SSRI non- and partial responders, switch to duloxetine was associated with significant improvement in emotional and painful symptoms of depression. Duloxetine was well tolerated and safe during both phases.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>24916728</pmid><doi>10.1080/13651500802578975</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1365-1501 |
| ispartof | International journal of psychiatry in clinical practice, 2009-01, Vol.13 (2), p.100-108 |
| issn | 1365-1501 1471-1788 |
| language | eng |
| recordid | cdi_pubmed_primary_24916728 |
| source | Taylor & Francis:Master (3349 titles); Taylor & Francis Medical Library - CRKN |
| subjects | Duloxetine major depressive disorder remission response selective serotonin reuptake inhibitor |
| title | Switching to duloxetine from selective serotonin reuptake inhibitors in non- or partial responders: Results from a Spanish sample |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T04%3A37%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Switching%20to%20duloxetine%20from%20selective%20serotonin%20reuptake%20inhibitors%20in%20non-%20or%20partial%20responders:%20Results%20from%20a%20Spanish%20sample&rft.jtitle=International%20journal%20of%20psychiatry%20in%20clinical%20practice&rft.au=Irene,%20Romera&rft.date=2009-01-01&rft.volume=13&rft.issue=2&rft.spage=100&rft.epage=108&rft.pages=100-108&rft.issn=1365-1501&rft.eissn=1471-1788&rft_id=info:doi/10.1080/13651500802578975&rft_dat=%3Cproquest_pubme%3E1535625329%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1535625329&rft_id=info:pmid/24916728&rfr_iscdi=true |